Results 81 - 90 of 208 : Previous 5 6 7 8 9 10 11 12 13 Next
The Less-Flashy Prostate Cancer Treatment
GTx shows off clinical trial data for a drug that counters the side effects of treatments.
A Positive Surprise for Genentech
Its lead drug gets a conditional OK to treat breast cancer.
Why Exelixis Might Be Out of Reach
With its shares in the dumps, is Exelixis going to be acquired?
Poor clinical trial data and a lack of profits hit the drugmaker hard.
Its top drugs get some protection, but free cash flow drops.
Schering-Plough Has No Love for the Media
The drug company pushes on after the Enhance trials.
The pharmaceutical's settlement ends a government probe.
The pharmaceutical issues guidance for the coming year.
Cash may be king in this market
PDL BioPharma Regroups, Piece by Piece
The company still brings in plenty of money, despite selling off assets.
Results 81 - 90 of 208 : Previous 5 6 7 8 9 10 11 12 13 Next
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK